Development of cancer metastasis suppression therapy focusing on the renin-angiotensin system

2020 Fiscal Year Final Research Report

• Project/Area Number: 18K06907
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 48030:Pharmacology-related
• Research Institution: University of Occupational and Environmental Health, Japan
• Principal Investigator: Ishikane Shin 産業医科大学, 医学部, 講師 (40470190)
• Project Period (FY): 2018-04-01 – 2021-03-31
• Keywords: アンギオテンシンII / 癌転移 / 悪性黒色腫 / 乳がん / 転移抑制薬

Outline of Final Research Achievements

In this study, we sought to elucidate the mechanisms by which angiotensin II (Ang II) exacerbates hematogenous metastasis in mouse tumor cells. Ang II exacerbates hematogenous metastasis of melanoma cells by promoting adhesion molecules-mediated adhesion of cancer cells to vascular endothelial cells. Ang II affected the fibroblasts around cancer cells to accelerate the tumor growth and facilitate metastasis formation and suggests the possibility that Ang II modifies tumor microenvironment.

Free Research Field

循環器疾患

Academic Significance and Societal Importance of the Research Achievements

本邦の高血圧患者は、厚生労働省による平成26年度調査報告では約1100万人とされ、今後も患者数の増加が予測される。癌患者における最も多い併発症は高血圧症であることからも、本研究による癌転移抑制療法の適応範囲は広く、高額負担なく、安全な治療法を行うことができることは医療費削減の観点からも非常に有益である。